Feed / AXSM

Axsome Therapeutics, Inc.

AXSM

Healthcare · 207.67 -0.2% today

Partial group confirmationMarket checked 21 Aug, 15:55 GMT-4

Jodie situation report

Axsome Therapeutics, Inc.'s move is being confirmed by its market group.

AXSM accounts for 1.5% of the group's measured movement across 5.6 effective names. raw member direction is mixed; 7 of 12 session-normalized paths align to the upside. Capital-flow agreement is 16%, so confirmation is not yet clean. No verified headline preceded the measured group move.

MOVE ANATOMY

Is this move genuinely shared?

Session-normalized 5m paths
Role in the moveFlat / inactive path#10 of 12 by movement share
Group movement share1.5%Absolute path energy—not portfolio weight
Relative path+0.35%flat
Effective breadth5.6 / 12balanced
Relative alignment7/12upside path · 1 counter-moving
Capital-flow agreement16%not yet clean
SEQUENCE READ

EWTX moved materially before AXSM. AXSM crossed its material path threshold at 15:50 ET. ALMS, GPCR, PRAX followed.

EVIDENCE COVERAGE

10 of 16 members in Clinical Biopharmaceuticals are active. 0 of 8 disclosed connections are confirming.

What would change this read
  • At least 11 of 16 durable members become active together.
  • Capital-flow agreement rises above 55%.
  • A filing-linked outsider such as NBIX begins moving with the group.

Invalidation: The live read weakens if participation falls to 5 of 16 members or fewer.

Watch this read

Who this business touches

The relationships behind AXSM

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

ABBVAbbVie Inc.competitorMay 4, 2026 ▾

“Among the companies that currently market or are developing therapies that, if approved, our product candidates would potentially compete with include: AbbVie; Amgen Inc.; Avadel Pharmaceuticals plc; Biogen Inc.; Eli Lilly and Company; H.”

AMGNAmgen Inc.competitorMay 4, 2026 ▾

“Among the companies that currently market or are developing therapies that, if approved, our product candidates would potentially compete with include: AbbVie; Amgen Inc.; Avadel Pharmaceuticals plc; Biogen Inc.; Eli Lilly and Company; H.”

Depended on by

DFTXDefinium Therapeutics, Inc.competitorFeb 26, 2026 ▾

“In addition, DT120 ODT would likely face competition from Axsome Therapeutics Inc.’s (“Axsome”) Auvelity, approved for the treatment of MDD.”

Filing peers

ALKSDFTXVNDA

Companies whose filings use similar operating language.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks 17 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

AXSM is currently a Participant in the organic co-movement group Clinical Biopharmaceuticals. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.